Islamic State & Gilead Sciences

Islamic State: Islamic State-backed militants contribute to the violence and insecurity in Democratic Republic of the Congo — Ituri Province, further complicating the Ebola response by disrupting health facilities and displacing populations.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Islamic State: Militants linked to the Islamic State group have carried out attacks in Democratic Republic of the Congo — Ituri Province, further complicating Ebola response efforts and displacing large populations.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Islamic State: Islamic State-affiliated ADF is active in the region, contributing to insecurity that hampers the Ebola response.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Islamic State: Militants linked to the Islamic State have conducted attacks in Ituri, exacerbating the security crisis and impeding humanitarian aid for the Ebola response.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Islamic State: Linked to ADF; indirect role via insecurity.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.